A pair of Baltimore biotech companies are getting $36M to create a new vaccine - Technical.ly Baltimore

Sciences

Aug. 16, 2018 4:38 pm

A pair of Baltimore biotech companies are getting $36M to create a new vaccine

Profectus Biosciences and Emergent Biosolutions are aiming to produce an antidote to the Lassa virus.

Emergent Biosolutions' Bayview facility.

(Courtesy photo)

Baltimore biotechs are teaming up in the fight against the Lassa virus.

Profectus Biosciences and Emergent Biosolutions will receive $36 million over five yearesin funding from the Oslo, Norway–based Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against the rat-borne virus. There is currently no vaccine for Lassa virus, which officials said is a threat to public health in West Africa. CEPI announced the deal Thursday.

Profectus, located off Dundalk Ave., will receive $4.3 million in Phase 1 to develop its Lassa vaccine. We’ve previously covered the company’s involvement in efforts to develop a vaccine for Ebola. Gaithersburg-based Emergent Biosolutions, a publicly-traded biopharmaceutical company with expanding manufacturing operations in the city, will provide technical and manufacturing assistance as part of the deal. In a release, Emergent specifically said its Center for Innovation in Advanced Development and Manufacturing in Bayview was designed to handle an increase in manufacturing during public health emergencies.

Advertisement

In turn, Profectus and Emergent have their own agreement that gives Emergent an exclusive option to license and continue to develop the vaccine.

While 80 percent of people who become infected show no symptoms, Nigeria is facing its largest-ever outbreak of the disease, which has resulted in 121 deaths. Outbreaks have also been reported in Liberia, Nigeria, Sierra Leone and South Sudan, according to CEPI.

The companies seem to have a Baltimore-centered partnership budding, as they also received a $25M grant from CEPI to develop a vaccine for Nipah virus earlier this year.

-30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here

Advertisement

The acquisition deal for Columbia-based Osiris Therapeutics is now complete

Baltimore’s Paragon Bioservices to be acquired by drug manufacturer Catalent for $1.2B

Paragon Bioservices expands, plans hires with new manufacturing facility

SPONSORED

Baltimore

How SmartLogic accelerated these startups’ product growth trajectories

Baltimore, MD 21201

14 West

Junior Database Administrator

Apply Now
Philadelphia, PA

Orthly

Full-Stack Javascript Engineer

Apply Now
Baltimore, MD 21201

14 West

Chief of Staff

Apply Now

Baltimore’s new health commish, Dr. Letitia Dzirasa, on community care and tech

LifeBridge Health and CareFirst are hosting an ‘innovation challenge’ for digital health startups

Columbia-based Osiris Therapeutics to be acquired in $660M deal

SPONSORED

Baltimore

This fast-growing SaaS company aims to be a force for change in the energy industry

Baltimore, MD

SmartLogic

Product Designer

Apply Now
Baltimore

Technically Media

Technical.ly Baltimore Contributing Reporter (Contract or Freelance)

Apply Now
Baltimore, MD

SmartLogic

Developer

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!